» Articles » PMID: 35145641

Podocyturia in Fabry Disease: a 10-year Follow-up

Overview
Journal Clin Kidney J
Specialty Nephrology
Date 2022 Feb 11
PMID 35145641
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fabry disease (FD) is a rare X-linked disorder of sphingolipid metabolism that results in chronic proteinuric nephropathy. Podocytes are one of the most affected renal cells and play an important role in the development and progression of kidney disease. Detached podocytes found in urine (podocyturia) are considered as a non-invasive early marker of kidney injury; however, the dynamics of podocyte loss remains unknown.

Methods: In this 10-year follow-up study, podocyturia and other renal clinical data were evaluated in 39 patients with FD. From 2009 to 2019, podocyturia was assessed in 566 fresh urine samples from 13 male and 26 female FD patients using immunocytochemical detection of podocalyxin.

Results: Podocyturia (number of podocytes per 100 mL of urine) was found in 311/566 (54.9%) of the samples, more frequently (68.9 ± 21.9% versus 50.6 ± 25.9%; P = 0.035) and with higher values (364 ± 286 versus 182 ± 180 number of podocytes per gram of creatinine (Cr) in urine; P = 0.020) in males compared with females. The mean number of assessed samples for each patient was 14.5 (range 3-40) and the frequency of samples with podocyturia ranged from 0% to 100% (median 57%). Podocyturia was already present in 42.9% of patients <20 years of age and in 89.5% of normoalbuminuric patients. Podocyturia correlated with albuminuria (urine albumin:Cr ratio) ( = 0.20, P < 0.001) and a higher incidence and values of podocyturia were observed in patients with lower estimated glomerular filtration rate.

Conclusions: Our data demonstrated that podocyturia is an early clinical event in the development of nephropathy. In addition, we found podocyturia to be a discontinuous event with wide variability.

Citing Articles

Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease.

Germain D, Linhart A Front Genet. 2024; 15:1395287.

PMID: 38680424 PMC: 11045972. DOI: 10.3389/fgene.2024.1395287.


Diagnosing Fabry nephropathy: the challenge of multiple kidney disease.

Esposito P, Caputo C, Repetto M, Somaschini A, Pietro B, Colomba P BMC Nephrol. 2023; 24(1):344.

PMID: 37990184 PMC: 10664682. DOI: 10.1186/s12882-023-03388-8.

References
1.
Trimarchi H, Canzonieri R, Costales-Collaguazo C, Politei J, Stern A, Paulero M . Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes. Clin Kidney J. 2019; 12(1):53-60. PMC: 6366138. DOI: 10.1093/ckj/sfy053. View

2.
Germain D . Fabry disease. Orphanet J Rare Dis. 2010; 5:30. PMC: 3009617. DOI: 10.1186/1750-1172-5-30. View

3.
Biegstraaten M, Arngrimsson R, Barbey F, Boks L, Cecchi F, Deegan P . Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015; 10:36. PMC: 4383065. DOI: 10.1186/s13023-015-0253-6. View

4.
Skoberne A, Konieczny A, Schiffer M . Glomerular epithelial cells in the urine: what has to be done to make them worthwhile?. Am J Physiol Renal Physiol. 2008; 296(2):F230-41. DOI: 10.1152/ajprenal.90507.2008. View

5.
Trimarchi H, Canzonieri R, Muryan A, Schiel A, Araoz A, Forrester M . Copious Podocyturia without Proteinuria and with Normal Renal Function in a Young Adult with Fabry Disease. Case Rep Nephrol. 2015; 2015:257628. PMC: 4443757. DOI: 10.1155/2015/257628. View